title: The dopamine transporter protein gene (SLC6A3): primary linkage mapping and linkage studies in Tourette syndrome.
abstract: The dopamine transporter, the molecule responsible for presynaptic reuptake of dopamine and a major site of action of psychostimulant drugs, including cocaine, is encoded by locus SLC6A3 (alias DAT1). The protein's actions and DAT's specific localization to dopaminergic neurons make it a candidate gene for several psychiatric illnesses. Alleles at this locus have been reported to be associated with cocaine-induced paranoia and attention deficit disorder. SLC6A3 has been mapped to distal chromosome 5p, using physical methods. Our goal was to place SLC6A3 in the genetic linkage map and to test for linkage to Tourette syndrome. Genetic linkage methods were used to place SLC6A3 in the genetic linkage map. Four extended pedigrees (one of which overlaps with CEPH) were typed. Linkage with Tourette syndrome (TS) was also examined. SLC6A3 showed close linkage with several markers previously mapped to distal chromosome 5p, including D5S11 (Zmax = 16.0, theta M = theta F = 0.03, results from four families) and D5S678 (Zmax = 7.84, theta M = theta F = 0, results from two families). Observed crossovers established that SLC6A3 is a distal marker close to D5S10 and D5S678, but these three distal markers could not be ordered. Linkage between TS and SLC6A3 could be excluded independently in two branches of a large kindred segregating TS; the lod score in a third family was also negative, but not significant. Cumulative results show a lod score of -6.2 at theta = 0 and of -3.9 at theta = 0.05 (dominant model, narrow disease definition). SLC6A3 thus maps to distal chromosome 5p by linkage analysis, in agreement with previous physical mapping data. A mutation at SLC6A3 is not causative for TS in the two large families that generated significant negative lod scores (if the parameters of our analyses were correct) and is unlikely to be causative in the family that generated a negative lod score that did not reach significance. These results do not exclude a role for the dopamine transporter in influencing risk for TS in combination with other loci.
authors.affiliation: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
authors.forename: J
authors.initials: J
authors.lastname: Gelernter
authors.forename: D
authors.initials: D
authors.lastname: Vandenbergh
authors.forename: S D
authors.initials: SD
authors.lastname: Kruger
authors.forename: D L
authors.initials: DL
authors.lastname: Pauls
authors.forename: R
authors.initials: R
authors.lastname: Kurlan
authors.forename: A J
authors.initials: AJ
authors.lastname: Pakstis
authors.forename: K K
authors.initials: KK
authors.lastname: Kidd
authors.forename: G
authors.initials: G
authors.lastname: Uhl
mesh_terms: D002352:Carrier Proteins / Q000235:genetics*; D002874:Chromosome Mapping; D003434:Crossing Over, Genetic; D050483:Dopamine Plasma Membrane Transport Proteins; D005260:Female; D008040:Genetic Linkage; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D010375:Pedigree; D005879:Tourette Syndrome / Q000235:genetics*
chemical_list: D002352:Carrier Proteins; D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; C493214:SLC6A3 protein, human